Osteoporosis is a skeletal pathology characterized by compromised bone strength leading to increased risk of fracture, mainly spine and hip fractures. Osteoporosis affects more than 200 million people worldwide and because of the skeletal fractures it causes, represents a major cause of morbidity, disability and mortality in older people. Recently the new discoveries of osteoimmunology have clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new immunological targets for its treatment opening the way for new and effective therapies with biological drugs. Currently, there are basically two monoclonal antibodies for osteoporosis therapy: denosumab and romosozumab. Here we focus on the modern approach to the osteoporosis management and in particular on current and developing biologic drugs targeted to new immunological checkpoints, in the landscape of osteoimmunology.

Osteoporosis: Current and emerging therapies targeted to immunological checkpoints

De Martinis, Massimo;Sirufo, Maria Maddalena;Ginaldi, Lia
2020

Abstract

Osteoporosis is a skeletal pathology characterized by compromised bone strength leading to increased risk of fracture, mainly spine and hip fractures. Osteoporosis affects more than 200 million people worldwide and because of the skeletal fractures it causes, represents a major cause of morbidity, disability and mortality in older people. Recently the new discoveries of osteoimmunology have clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new immunological targets for its treatment opening the way for new and effective therapies with biological drugs. Currently, there are basically two monoclonal antibodies for osteoporosis therapy: denosumab and romosozumab. Here we focus on the modern approach to the osteoporosis management and in particular on current and developing biologic drugs targeted to new immunological checkpoints, in the landscape of osteoimmunology.
File in questo prodotto:
File Dimensione Formato  
Osteoporosis CURR MED CHEM 2019.pdf

accesso aperto

Tipologia: Documento in Pre-print
Licenza: Creative commons
Dimensione 959.05 kB
Formato Adobe PDF
959.05 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11697/136494
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 42
social impact